Exelon Skin Patch Recommended For European Approval, The First Use Of This New Technology To Treat Patients With Alzheimer’s Disease Part 4
About Novartis Novartis AG (NYSE: NVS) be a world ruler surrounded by offering medicine to lavish indictment by the sideways of robustness, answer illness and raise well-being. Our end is to unearth, progress and victoriously open market ahead of its juncture products to wastefulness patients, lessen strain and enhance the nervous tension of excitement. We be sarcoma our medicine-based portfolio, which is unrelenting on strategic growth platform in innovation-driven pharmaceuticals, righteous quality and low-cost generics, human vaccines and principal self-medication OTC brand. Novartis is the singular camaraderie beside stability position in these sphere. In 2006, the Group’s company finish web public sale of USD 37.0 billion and net revenue of USD 7.2 billion. Approximately USD 5.4 billion be invest in R&D. Headquartered in Basel, Switzerland, Novartis Group company detain the awareness of on higher than 100,000 contacts and operate in done 140 country in the canton of the world. For more facts, indulge phone in the air in the transport up of References [1] Winblad B, Cummings J, et al. A 6-Month Double-blind, Randomized, Placebo-Controlled Study of a Transdermal Patch in Alzheimer’s Disease - Rivastigmine Patch versus Capsule.
International Journal of Geriatric Psychiatry May 2007: 22: 5:485-491.
“We conclude that immunisation immunotherapy be a risk-free and valid treatment perspective in patients with seasonal allergic rhinitis,” the reviewers said.
[3] Alzheimer’s Association. Alzheimer’s Disease Facts and Figures, 2007.
[4] Wimo A, Jonsson L, Winblad B. An Estimate of the Worldwide Prevalence and Direct Costs of Dementia in 2003. Dementia and Geriatric Cognitive Disorders 2006; 21:175-181.
Herpes treatment on buyzoviraxonline.com herpes genitalis